Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 909-919

  Martín, Mónica ^a   de Paz, Raquel ^b   Jiménez Yuste, Víctor ^a   Bello, Ihosvany Fernández ^a   Salgado, Elena García Arias ^a   Álvarez, María Teresa ^a   Butta, Nora V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Gp iib iiia activation; Myelodysplastic syndromes; Platelet apoptosis; Platelet pathology

Indexed keywords

CASPASE; LIPOCORTIN 5; PROCOAGULANT; PROTEIN BAK; PROTEIN BAX; THROMBOPOIETIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MULTIPOTENT STEM CELL; MYELODYSPLASTIC SYNDROME; PLATELET APOPTOSIS; PLATELET MICROPARTICLE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; WESTERN BLOTTING;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANNEXIN A5; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BLOOD COAGULATION; BLOOD PLATELETS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CASPASES; CELL-DERIVED MICROPARTICLES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET COUNT; THROMBELASTOGRAPHY; THROMBIN; THROMBOCYTOPENIA; THROMBOPOIETIN; YOUNG ADULT;

EID: 84877033321     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-09-0670     Document Type: Article

References (49)

1. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001; 73: 405-410.
2. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002; 136-161.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
6. Gonzalez-Porras JR, Cordoba I, Such E, et al. Prognostic Impact of Severe Thrombocytopenia in Low-Risk Myelodysplastic Syndrome. Cancer 2011; 117: 5529-5537.
7. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005; 105: 3472-3479.
8. Kile BT. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009; 7 (Suppl 1): 214-217.
9. Hayashi S, Oshida M, Kiyoi T, et al. Reticulated platelet determination: methodologies and applications for the evaluation of thrombocytopenic disorders. Rinsho Ketsueki 1999; 40: 205-212.
10. Hemker HC, Giesen PLA, Ramjee M, et al. Thrombogram: Monitoring Thrombin Generation in Platelet Rich Plasma. Thromb Haemost 2000; 83: 589-591.
11. Ichikawa N, Ishida F, Shimodaira S, et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996; 76: 156-160.
12. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-4071.
13. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-121.
14. Bowles KM, Warner BA, Baglin TP. Platelet mass has prognostic value in patients with myelodysplastic syndromes. Br J Haematol 2006; 135: 198-200.
15. Germing U, Platzbecker U, Giagounidis A, et al. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Br J Haematol 2007; 138: 396-403.
16. Girtovitis FI, Ntaios G, Papadopoulos A, et al. Defective Platelet Aggregation in Myelodysplastic Syndromes. Acta Haematol 2007; 118: 117-122.
17. Raman BK, Van Slyck EJ, Riddle J, et al. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 1989; 91: 647-655.
18. Sandes AF, Yamamoto M, Matarraz S, et al. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica 2012; 97: 895-902.
19. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007; 13: 1086-1095.
20. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-11108.
21. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 419-431.
22. Tamura H, Ogata K, Luo S, et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 1998; 103: 778-784.
23. Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
24. Monteagudo M, Amengual MJ, Munoz L, et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101: 549-555.
25. Saigo K, Takenokuchi M, Imai J, et al. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. Lab Hematol 2009; 15: 13-16.
26. Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasmaglycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001; 115: 656-664.
27. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-241.
28. Kodama T, Takehara T, Hikita H, et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by BclxL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011; 286: 13905-13913.
29. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
30. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
31. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
32. Tse C, Shoemaker AR, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
33. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.
34. Schoenwaelder S, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.
35. Zeidman A, Sokolover N, Fradin Z, et al. Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 2004; 5: 234-238.
36. Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86: 266-275.
37. Bevers EM, Comfurius P, Dekkers DW et al. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys Acta 1999; 1439: 317-330.
38. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
39. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-17057.
40. Comfurius P, Senden JM, Tilly RH, et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026: 153-160.
41. Morel O, Toti F, Hugel B, et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
42. Fuhler GM, Knol GJ, Drayer AL, et al. Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol 2005; 77: 257-266.
43. Fuhler GM, Blom NR, Coffer PJ, et al. The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation. J Leukoc Biol 2007; 81: 449-457.
44. Fianchi L, Leone G, Posteraro B, et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res 2012; 36: 331-333.
45. Kantarjian H, Issa J-PJ, Rosenfeld C, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006; 106: 1794-1803.
46. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyl-transferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007; 109: 4158-4163.
47. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
48. Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005; 1285: 625-630.
49. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.